NYSE - Nasdaq Real Time Price USD

Merck & Co., Inc. (MRK)

125.78

+0.55

(+0.44%)

At close: April 19 at 4:01 PM EDT

125.40

-0.38

(-0.30%)

After hours: April 19 at 7:54 PM EDT

Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. This approval is based on the results from the Phase 3 KEYNOTE-859 trial, whic

CNW Group 17 hours ago

MRK
+0.44%
13 Best Low Volatility Stocks to Buy According to Hedge Funds

In this article, we discuss the 13 best low volatility stocks to buy according to hedge funds. To skip the detailed analysis of the current market conditions, go directly to the 5 Best Low Volatility Stocks to Buy According to Hedge Funds. The S&P 500 had a remarkable year in 2023 and the first quarter […]

Insider Monkey yesterday

^GSPC

^VIX

TSM
Merck Insiders Sold US$15m Of Shares Suggesting Hesitancy

The fact that multiple Merck & Co., Inc. ( NYSE:MRK ) insiders offloaded a considerable amount of shares over the past...

Simply Wall St. 2 days ago

MRK
+0.44%
10 Best Low Volatility ETFs To Buy

In this article, we discuss 10 best low volatility ETFs to buy. If you want to skip our discussion on low volatility investments, head over to 5 Best Low Volatility ETFs To Buy. What is Low Volatility Investing? Low volatility investing refers to an investment strategy where a stock portfolio is less volatile in terms […]

Insider Monkey 4 days ago

MSFT

STLAM.MI

MRK
+0.44%
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

The best biotech stocks to buy are in companies that put a lot of resources into research and development, often with nothing to show for it for years. Regulatory hurdles make finding biotech stocks to buy challenging if you don’t have the patience to wait it out. But when biotech companies win approval to sell and marketing a drug, the potential for profits can be off the charts. That’s why it’s a good idea to at least consider biotech, and whether they have a spot in your portfolio.InvestorPla

InvestorPlace 7 days ago

MRK
+0.44%
NVO

APM
Merck & Co., Inc.'s (NYSE:MRK) Stock Financial Prospects Look Bleak: Should Shareholders Be Prepared For A Share Price Correction?

Merck's (NYSE:MRK) stock is up by 7.0% over the past three months. However, its weak financial performance indicators...

Simply Wall St. 8 days ago

MRK
+0.44%
Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study

Data from an early-stage study shows that treatment with Moderna's (MRNA) experimental cancer therapy achieved positive clinical response in patients with a specific type of head and neck cancer.

Zacks 9 days ago

MRNA

ADMA

ANIP
Company News for Apr 10, 2024

Companies in The News Are: MRNA, MRK, COIN, BN, NEOG

Zacks 9 days ago

MRNA

NEOG

COIN
Golden Years Gainers: 3 Stocks to Fund Your Dream Retirement

Most people consider retirement one of the most important events to prepare for. Focusing on long-term investments, preferably with strong dividend yields, is a great way to get started. With compounding interest and dividend growth, investors who take investing and saving for retirement seriously can become very profitable over a number of decades. Here are a number of stocks that provide investors with a fantastic start to a long-term investment portfolio for growth as well as overall income g

InvestorPlace 11 days ago

MRK
+0.44%
CMCSA

VICI
The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024

Looking ahead, the future of the U.S. economy appears promising despite ongoing challenges. President Biden’s efforts to steer the economy through inflation concerns are showing strong results. Recent data indicates a healthy economic position, with significant GDP growth outpacing other developed nations. Despite fluctuations in inflation and interest rates, the U.S. labor market remains resilient, adding jobs at a rapid pace. The country’s economic resilience, bolstered by substantial fiscal s

InvestorPlace 12 days ago

AMGN
+2.35%
HD
+0.74%
MRK
+0.44%
10 Best Weight Loss Drug Stocks to Buy Now

In this piece, we will take a look at the ten best weight loss drug stocks to buy now. If you want to skip our introduction to the rising weight loss drug industry and how it’s one of the biggest trends on the stock market right now, then you can take a look at the […]

Insider Monkey 13 days ago

LLY
-2.63%
NVO

VKTX
The three-year decline in earnings for Merck NYSE:MRK) isn't encouraging, but shareholders are still up 93% over that period

By buying an index fund, you can roughly match the market return with ease. But if you choose individual stocks with...

Simply Wall St. 13 days ago

MRK
+0.44%
Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Merck (MRK) concluded the recent trading session at $127.99, signifying a +0.26% move from its prior day's close.

Zacks 14 days ago

MRK
+0.44%
Merck puts KRAS cancer drug competitor to the test

A Phase 3 study will compare Merck’s experimental KRAS inhibitor together with its immunotherapy Keytruda against Keytruda alone in lung cancer.

BioPharma Dive 15 days ago

MRK
+0.44%
AMGN
+2.35%
CELG-RT
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer

RAHWAY, N.J., April 04, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced it has initiated a Phase 3 clinical trial evaluating MK-1084, an investigational oral selective KRAS G12C inhibitor, in combination with KEYTRUDA for the first-line treatment of certain patients with metastatic non-small cell lung cancer (NSCLC) whose tumors harbor KRAS G12C mutations and express PD-L1 (tumor proportion score [TPS] ≥50%).

Business Wire 15 days ago

MRK
+0.44%
Merck (MRK) Stock Sinks As Market Gains: What You Should Know

Merck (MRK) reachead $129.90 at the closing of the latest trading day, reflecting a -0.35% change compared to its last close.

Zacks 16 days ago

MRK
+0.44%
REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer

BASKING RIDGE, N.J. & RAHWAY, N.J., April 03, 2024--REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer

Business Wire 16 days ago

DSKYF

DSNKY

MRK
+0.44%
Why Merck (MRK) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks 18 days ago

MRK
+0.44%
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25

RAHWAY, N.J., April 01, 2024--Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25

Business Wire 18 days ago

MRK
+0.44%
3 Strong Buy Healthcare Stocks to Add to Your Q2 Must-Watch List

As the number of grey-haired people rises worldwide, investors need to notice the strong-buy healthcare stocks. The need for healthcare will grow as the number of people aged 60 years and older doubles by 2050, a situation never before witnessed in the world, thanks to smaller families and longer lifespans. All of this is great for strong buy healthcare stocks as they can target a huge addressable market. U.S. healthcare spending is estimated to reach a total market value of about $6.2 trillion

InvestorPlace 21 days ago

UNH

ABT
+1.91%
MRK
+0.44%

Performance Overview

Return	MRK	S&P 500
YTD	+16.11%	+4.14%
1-Year	+12.53%	+19.55%
3-Year	+86.64%	+18.68%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Merck & Co., Inc. (MRK)

Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and platinum-containing chemotherapy

13 Best Low Volatility Stocks to Buy According to Hedge Funds

Merck Insiders Sold US$15m Of Shares Suggesting Hesitancy

10 Best Low Volatility ETFs To Buy

7 A-Rated Aggressive Biotech Stocks to Bet On in 2024

Merck & Co., Inc.'s (NYSE:MRK) Stock Financial Prospects Look Bleak: Should Shareholders Be Prepared For A Share Price Correction?

Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study

Company News for Apr 10, 2024

Golden Years Gainers: 3 Stocks to Fund Your Dream Retirement

The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024

10 Best Weight Loss Drug Stocks to Buy Now

The three-year decline in earnings for Merck NYSE:MRK) isn't encouraging, but shareholders are still up 93% over that period

Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Merck puts KRAS cancer drug competitor to the test

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer

Why Merck (MRK) is a Top Momentum Stock for the Long-Term

Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25

3 Strong Buy Healthcare Stocks to Add to Your Q2 Must-Watch List

Performance Overview